Cargando…
A novel mouse model of cutaneous T‐cell lymphoma revealed the combined effect of mogamulizumab with psoralen and ultraviolet a therapy
Mycosis fungoides (MF) is a subtype of cutaneous T‐cell lymphoma (CTCL). Topical or systemic treatment with psoralen, such as 8‐methoxypsoralen (8‐MOP), followed by ultraviolet A (UVA) irradiation (PUVA therapy) is an effective phototherapy for early‐stage MF. However, the efficacy of PUVA therapy f...
Autores principales: | Nakahashi, Keiko, Nihira, Kaito, Suzuki, Miyoko, Ishii, Toshihiko, Masuda, Kazuhiro, Mori, Kiyotoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796778/ https://www.ncbi.nlm.nih.gov/pubmed/35801380 http://dx.doi.org/10.1111/exd.14641 |
Ejemplares similares
-
Psoralen-ultraviolet A treatment with Psoralen-ultraviolet B therapy in the treatment of psoriasis
por: Ahmed Asim, Sadaf, et al.
Publicado: (2013) -
Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma
por: Ollila, Thomas A, et al.
Publicado: (2019) -
Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma
por: Watson, Sutton, et al.
Publicado: (2019) -
Italian Real-Life Experience on the Use of Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas
por: Caruso, Laura, et al.
Publicado: (2022) -
Quality of Life in Cutaneous T-cell Lymphoma Patients Receiving Mogamulizumab: Important Factors to Consider
por: Ottevanger, Rosanne, et al.
Publicado: (2022)